Silent and non‐silent thromboembolic events after ventricular tachycardia ablation: Modifiable risk with postprocedure anticoagulation?

There is increasing recognition of silent and clinically apparent thromboembolic events after left‐sided ventricular tachycardia (VT) ablation. However, unlike atrial fibrillation ablation procedures where postablation oral anticoagulation (OAC) is universal, there is significant practice variation in OAC use after VT ablation. Herein, we review the data on post‐VT ablation thromboembolism and evidence on the use of OAC, we suggest that OAC merits consideration in most cases after a balanced assessment of risks and benefits in individual patients, and we discuss future directions.